NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SteadyMed Ltd. ("SteadyMed" or the "Company") (NASDAQ: STDY). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/stdy.
The investigation concerns whether SteadyMed and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On August 31, 2017, SteadyMed revealed that it received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") regarding it New Drug Application ("NDA") for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. Following this news, SteadyMed stock has dropped as much as $2.65 per share, or 44.92%, during intraday trading on August 31, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of SteadyMed, you can assist this investigation by visiting the firm's site: www.bgandg.com/stdy. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.